Ligand Pharmaceuticals (LGND) News Today $120.78 -1.92 (-1.56%) (As of 12:54 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Insider Selling: Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Director Sells 2,406 Shares of StockDecember 3 at 4:21 AM | insidertrades.com34,069 Shares in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Bought by Edgestream Partners L.P.Edgestream Partners L.P. bought a new position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund bought 34,069 shares of the biotechnology company's stock, valued at approximately $3,41December 2 at 5:28 AM | marketbeat.comIsthmus Partners LLC Sells 9,622 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Isthmus Partners LLC trimmed its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 20.0% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 38,554 shares of the biotechnology company's stockNovember 29, 2024 | marketbeat.comFisher Asset Management LLC Boosts Stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Fisher Asset Management LLC boosted its stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 12.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 59,574 shares of the biNovember 29, 2024 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives $144.83 Average Price Target from BrokeragesNovember 27, 2024 | americanbankingnews.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Acquired by Loomis Sayles & Co. L PLoomis Sayles & Co. L P increased its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 44.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 372,779 shares of the biotechnology cNovember 26, 2024 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Acquired by Victory Capital Management Inc.Victory Capital Management Inc. increased its stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 79.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,022 sNovember 26, 2024 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Acquires 9,667 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 55.9% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 26,963 shares of the bioteNovember 25, 2024 | marketbeat.comLigand Pharmaceuticals: Buy This Strong Growing Pharma And Get A Stake In Dozens Of TherapiesNovember 24, 2024 | seekingalpha.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Average Recommendation of "Buy" from AnalystsShares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Get Free Report) have received an average rating of "Buy" from the six brokerages that are presently covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The aveNovember 22, 2024 | marketbeat.comRoyce & Associates LP Sells 4,996 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Royce & Associates LP trimmed its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 45.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,090 shares of the biotechnology companNovember 21, 2024 | marketbeat.comLigand to Present at Stifel 2024 Healthcare ConferenceNovember 14, 2024 | finance.yahoo.comLGND: 3Q Sales Surprise to the UpsideNovember 12, 2024 | finance.yahoo.comRBC Capital Keeps Their Buy Rating on Ligand Pharma (LGND)November 12, 2024 | markets.businessinsider.comLigand Pharmaceuticals (NASDAQ:LGND) Given New $140.00 Price Target at Royal Bank of CanadaRoyal Bank of Canada raised their price target on Ligand Pharmaceuticals from $130.00 to $140.00 and gave the company an "outperform" rating in a research report on Tuesday.November 12, 2024 | marketbeat.comLisanti Capital Growth LLC Buys New Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Lisanti Capital Growth LLC bought a new stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 24,785 shares ofNovember 11, 2024 | marketbeat.comBarclays Sticks to Its Buy Rating for Ligand Pharma (LGND)November 9, 2024 | markets.businessinsider.comLigand Pharmaceuticals Reports Strong Q3 2024 GrowthNovember 9, 2024 | markets.businessinsider.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Sold by Villere ST Denis J & Co. LLCVillere ST Denis J & Co. LLC cut its holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 1.9% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 474,858 shares of the biotechnology company's stock after selling 9,055 shares during theNovember 9, 2024 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Given New $135.00 Price Target at BenchmarkBenchmark lifted their target price on Ligand Pharmaceuticals from $110.00 to $135.00 and gave the stock a "buy" rating in a report on Friday.November 8, 2024 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Trading Down 7.7% - Time to Sell?Ligand Pharmaceuticals (NASDAQ:LGND) Trading Down 7.7% - What's Next?November 8, 2024 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Given New $150.00 Price Target at BarclaysBarclays boosted their price objective on shares of Ligand Pharmaceuticals from $125.00 to $150.00 and gave the company an "overweight" rating in a report on Friday.November 8, 2024 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Price Target Raised to $147.00Oppenheimer boosted their target price on Ligand Pharmaceuticals from $135.00 to $147.00 and gave the company an "outperform" rating in a research note on Friday.November 8, 2024 | marketbeat.comLigand price target raised to $150 from $125 at BarclaysNovember 8, 2024 | msn.comLigand Pharmaceuticals Incorporated (LGND) Q3 2024 Earnings Call TranscriptNovember 8, 2024 | seekingalpha.comLigand Pharmaceuticals Incorporated's (NASDAQ:LGND) Intrinsic Value Is Potentially 99% Above Its Share PriceNovember 8, 2024 | finance.yahoo.comLigand Pharmaceuticals Inc (LGND) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...November 8, 2024 | finance.yahoo.comLigand Pharmaceuticals (NASDAQ:LGND) Receives "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $157.00 target price on shares of Ligand Pharmaceuticals in a research note on Friday.November 8, 2024 | marketbeat.comLigand Pharma’s Strong Financial Performance and Strategic Growth Justifies Buy RatingNovember 8, 2024 | markets.businessinsider.comLigand Pharmaceuticals Q3 2024 Earnings PreviewNovember 7, 2024 | msn.comLigand Pharmaceuticals Boosts FY24 Outlook - UpdateNovember 7, 2024 | markets.businessinsider.comLigand Pharmaceuticals Inc (LGND) Q3 2024: Everything You Need To Know Ahead Of EarningsNovember 7, 2024 | finance.yahoo.comLigand Pharmaceuticals (NASDAQ:LGND) Updates FY24 Earnings GuidanceLigand Pharmaceuticals (NASDAQ:LGND) updated its FY24 earnings guidance. The company provided EPS guidance of $5.50-5.70 for the period, compared to the consensus estimate of $5.39. The company also issued revenue guidance of $160-165 millionillion, compared to the consensus estimate of $156.29 millionillion.November 7, 2024 | marketbeat.comLigand to Host Investor and Analyst Day on December 10, 2024 in BostonNovember 1, 2024 | businesswire.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Sold by Stephens Investment Management Group LLCStephens Investment Management Group LLC lessened its stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 5.1% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 618,696 shares of the biotechnology company'November 1, 2024 | marketbeat.comStrategic Growth and Revenue Potential Drive Buy Rating for Ligand PharmaNovember 1, 2024 | markets.businessinsider.comCongress Asset Management Co. Buys 17,414 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Congress Asset Management Co. grew its stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 3.0% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 604,038 shares of the biotechnology company's stock after acqOctober 31, 2024 | marketbeat.comLigand Pharmaceuticals' (LGND) Buy Rating Reiterated at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $157.00 target price on shares of Ligand Pharmaceuticals in a research note on Thursday.October 31, 2024 | marketbeat.comLigand Pharmaceuticals (LGND) Scheduled to Post Earnings on ThursdayLigand Pharmaceuticals (NASDAQ:LGND) will be releasing earnings before the market opens on Thursday, November 7, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=639045)October 31, 2024 | marketbeat.comLigand price target raised to $125 from $110 at BarclaysOctober 29, 2024 | markets.businessinsider.comLigand Pharmaceuticals (NASDAQ:LGND) PT Raised to $125.00Barclays increased their price objective on Ligand Pharmaceuticals from $110.00 to $125.00 and gave the stock an "overweight" rating in a report on Monday.October 28, 2024 | marketbeat.comAllspring Global Investments Holdings LLC Raises Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Allspring Global Investments Holdings LLC boosted its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 16.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 115,4October 26, 2024 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Sets New 52-Week High - What's Next?Ligand Pharmaceuticals (NASDAQ:LGND) Hits New 1-Year High - Time to Buy?October 25, 2024 | marketbeat.comLigand to Report Third Quarter 2024 Financial Results on November 7, 2024October 23, 2024 | businesswire.comCritical Insights From Ligand Pharmaceuticals Analyst Ratings: What You Need To KnowOctober 21, 2024 | benzinga.comLigand Pharmaceuticals (NASDAQ:LGND) PT Raised to $157.00HC Wainwright increased their price objective on Ligand Pharmaceuticals from $144.00 to $157.00 and gave the company a "buy" rating in a report on Monday.October 21, 2024 | marketbeat.comChicago Capital LLC Has $54.63 Million Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Chicago Capital LLC lifted its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 6.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 545,821 shares of the biotechnology company's stOctober 20, 2024 | marketbeat.comStrategic Deals and Royalty Expansion Drive Ligand Pharma’s Promising Growth TrajectoryOctober 19, 2024 | markets.businessinsider.comAQR Capital Management LLC Cuts Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)AQR Capital Management LLC trimmed its stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 78.2% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,924 shares of the biotechnOctober 16, 2024 | marketbeat.comLigand Pharmaceuticals Inc (LGND) Q2 2024 Earnings Call Highlights: Robust Revenue Growth Amid ...October 10, 2024 | finance.yahoo.com Get Ligand Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LGND and its competitors with MarketBeat's FREE daily newsletter. Email Address This company will win the AI race (Ad)Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. You must read this new presentation from Porter Stansberry. LGND Media Mentions By Week LGND Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LGND News Sentiment▼1.400.87▲Average Medical News Sentiment LGND News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LGND Articles This Week▼74▲LGND Articles Average Week Get Ligand Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LGND and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RGEN News Today MDGL News Today HALO News Today IONS News Today ALKS News Today FOLD News Today GERN News Today CLDX News Today MNKD News Today DVAX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LGND) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredEven Trump can’t stop what’s coming.No matter who sits in the White House over the next four years, a series of events has been triggered that cou...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ligand Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Ligand Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
